CVS Health Target of Unusually Large Options Trading (NYSE:CVS)

CVS Health Corporation (NYSE:CVS) was the target of some unusual options trading activity on Thursday. Stock investors bought 117,299 call options on the company. This is an increase of approximately 461% compared to the average volume of 20,922 call options.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Analysts and market commentary pointed to improving execution, stronger payer margins, and a modest lift in CVS’s fair value estimate, suggesting Wall Street sees more upside in the stock. CVS Health (CVS) Stock Sees Modest Fair Value Lift As Analysts Raise Targets
• Positive Sentiment: Options activity was unusually strong, with traders buying far more call options than normal, which can signal expectations for continued upside.
• Positive Sentiment: CVS’s new nationwide pet-prescription service has generated widespread coverage and could support pharmacy traffic and customer engagement. CVS is making it easier for pet owners with a new perk
• Neutral Sentiment: Brokerage coverage remains constructive, with CVS receiving a consensus “Moderate Buy” rating and another recent upgrade to Buy, reinforcing a generally favorable analyst stance. CVS Health Corporation (NYSE:CVS) Receives Consensus Rating of “Moderate Buy” from Brokerages
• Neutral Sentiment: Several articles highlighted CVS’s community-health investments in Massachusetts, but these are more reputational than immediately material to earnings. CVS Health Helping to Strengthen Communities Across Massachusetts
• Negative Sentiment: Henry Ford Health filed a lawsuit against CVS alleging a 340B pricing scheme, which could create legal and reputational risk if the claims gain traction. Henry Ford Health sues CVS, alleges 340B pricing scheme

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CVS. Bank of America upped their price objective on shares of CVS Health from $100.00 to $110.00 and gave the company a “buy” rating in a report on Monday, June 22nd. Argus raised their target price on CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a research note on Thursday, May 14th. Cantor Fitzgerald boosted their target price on CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a research report on Tuesday, July 7th. Wells Fargo & Company upped their price target on CVS Health from $103.00 to $123.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Finally, UBS Group raised their price objective on CVS Health from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, June 8th. Twenty-one research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.38.

Insider Transactions at CVS Health

In other news, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the sale, the director owned 4,824,799 shares in the company, valued at $450,877,466.55. The trade was a 7.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 3,441,551 shares of company stock valued at $323,703,977. Company insiders own 0.85% of the company’s stock.

Institutional Investors Weigh In On CVS Health

Several large investors have recently made changes to their positions in the business. Norges Bank bought a new position in CVS Health during the fourth quarter valued at $1,666,265,000. Wellington Management Group LLP raised its stake in shares of CVS Health by 193.2% in the fourth quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock valued at $1,473,270,000 after buying an additional 12,233,675 shares during the period. Pacer Advisors Inc. lifted its position in shares of CVS Health by 1,020.7% during the 1st quarter. Pacer Advisors Inc. now owns 4,845,221 shares of the pharmacy operator’s stock valued at $347,984,000 after buying an additional 4,412,882 shares during the last quarter. Amundi grew its stake in shares of CVS Health by 95.3% during the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock worth $572,665,000 after acquiring an additional 3,637,943 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its stake in shares of CVS Health by 44.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,219,756 shares of the pharmacy operator’s stock worth $446,703,000 after acquiring an additional 1,899,932 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Stock Down 1.1%

CVS Health stock opened at $106.86 on Friday. The firm has a market capitalization of $136.35 billion, a price-to-earnings ratio of 47.08, a price-to-earnings-growth ratio of 1.06 and a beta of 0.61. The firm’s fifty day moving average price is $99.98 and its two-hundred day moving average price is $85.97. CVS Health has a 1-year low of $58.50 and a 1-year high of $110.68. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same quarter in the prior year, the business posted $2.25 EPS. The firm’s revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, equities research analysts predict that CVS Health will post 7.46 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 23rd will be issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Thursday, July 23rd. CVS Health’s dividend payout ratio (DPR) is 117.18%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.